Phase II evaluation of chlorozotocin in patients with renal cell carcinoma

R. J. Gralla, A. Yagoda

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Because of reports of occasional objective responses in renal cell carcinoma with chlorozotocin in phase I studies and reported activity of CCNU in this disease, the present phase II study was initiated. Twenty-one patients with histologically confirmed unresectable renal cell carcinoma were entered in this study between June 1977 and February 1978. No significant tumor regression occurred in the 21 chlorozotocin-treated patients. The treatment group included patients with a good PS who experienced myelosuppression secondary to chlorozotocin. In addition, 14 of 21 (67%) of the patients had received no prior hormonal or myelosuppressive chemotherapy. Because no PRs were achieved in this number of patients, it can be concluded that chlorozotocin is likely to have a true major response rate of <15%. The drug would appear to have little therapeutic value in this schedule as a single agent in patients with advanced renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)1007-1008
Number of pages2
JournalCancer Treatment Reports
Issue number6
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II evaluation of chlorozotocin in patients with renal cell carcinoma'. Together they form a unique fingerprint.

Cite this